<p>French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their Covid-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organization.</p>.<p>The companies said on Wednesday they have signed a statement of intent with vaccine alliance GAVI, which is coordinating the global plan known as COVAX.</p>.<p>COVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan.</p>.<p>The United States and UK are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines.</p>.<p><a href="https://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank"><strong>Follow DH's coverage of the Covid-19 pandemic here</strong></a></p>.<p>GSK-Sanofi has currently signed a $2.1 billion deal with the US to supply it with more than 100 million doses of its coronavirus vaccine candidate. The companies also have deals with the European Union and UK.</p>.<p>The first results from an early mid-stage study of the Sanofi-GSK vaccine are expected in early December 2020, and the companies plan to file for regulatory approval in 2021.</p>.<p>The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK. </p>
<p>French drugmaker Sanofi SA and Britain's GlaxoSmithKline plan to make 200 million doses of their Covid-19 vaccine candidate available to the vaccine allocation plan co-led by GAVI and the World Health Organization.</p>.<p>The companies said on Wednesday they have signed a statement of intent with vaccine alliance GAVI, which is coordinating the global plan known as COVAX.</p>.<p>COVAX aims to deliver 2 billion vaccine doses around the world by the end of 2021, and more than 180 nations have joined the plan.</p>.<p>The United States and UK are leading a rush to strike deals with drugmakers to reserve supplies of experimental coronavirus vaccines.</p>.<p><a href="https://www.deccanherald.com/coronavirus-live-news-covid-19-latest-updates.html" target="_blank"><strong>Follow DH's coverage of the Covid-19 pandemic here</strong></a></p>.<p>GSK-Sanofi has currently signed a $2.1 billion deal with the US to supply it with more than 100 million doses of its coronavirus vaccine candidate. The companies also have deals with the European Union and UK.</p>.<p>The first results from an early mid-stage study of the Sanofi-GSK vaccine are expected in early December 2020, and the companies plan to file for regulatory approval in 2021.</p>.<p>The vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the vaccine, made by GSK. </p>